DK1924561T3 - 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister - Google Patents
6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonisterInfo
- Publication number
- DK1924561T3 DK1924561T3 DK06802859.6T DK06802859T DK1924561T3 DK 1924561 T3 DK1924561 T3 DK 1924561T3 DK 06802859 T DK06802859 T DK 06802859T DK 1924561 T3 DK1924561 T3 DK 1924561T3
- Authority
- DK
- Denmark
- Prior art keywords
- azepiner
- agonister
- arylalkylamino
- benzo
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05380191 | 2005-09-01 | ||
US73108105P | 2005-10-28 | 2005-10-28 | |
PCT/US2006/034335 WO2007028083A2 (en) | 2005-09-01 | 2006-09-01 | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1924561T3 true DK1924561T3 (da) | 2012-12-10 |
Family
ID=39892208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06802859.6T DK1924561T3 (da) | 2005-09-01 | 2006-09-01 | 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister |
Country Status (13)
Country | Link |
---|---|
US (2) | US20080269196A1 (da) |
EP (1) | EP1924561B1 (da) |
JP (1) | JP5155864B2 (da) |
CN (1) | CN101258131B (da) |
AU (1) | AU2006287202B2 (da) |
BR (1) | BRPI0615048A2 (da) |
CA (1) | CA2619448C (da) |
DK (1) | DK1924561T3 (da) |
ES (1) | ES2397400T3 (da) |
PL (1) | PL1924561T3 (da) |
PT (1) | PT1924561E (da) |
SI (1) | SI1924561T1 (da) |
WO (1) | WO2007028083A2 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5237810B2 (ja) * | 2005-09-01 | 2013-07-17 | イーライ リリー アンド カンパニー | 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン |
US7981882B2 (en) * | 2005-09-01 | 2011-07-19 | Eli Lilly And Company | 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体拮抗薬としてのインダゾール化合物 |
CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
EP2346868B1 (en) | 2008-09-26 | 2016-01-27 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
CA2778060A1 (en) | 2009-10-21 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
JP5542214B2 (ja) | 2009-10-27 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体アンタゴニストとしての複素環化合物 |
JP2013512954A (ja) * | 2009-12-08 | 2013-04-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換インダゾール及びアザインダゾール化合物の生成に有効な中間体の合成方法 |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
WO2012030953A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
JP5684406B2 (ja) | 2010-12-23 | 2015-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体アンタゴニストとしてのピラゾロピペリジン化合物 |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
DK3511319T3 (da) * | 2014-07-03 | 2023-07-31 | Celgene Quanticel Res Inc | Hæmmere af lysinspecifik demethylase-1 |
CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
JPWO2017195894A1 (ja) * | 2016-05-13 | 2019-03-14 | 日産化学株式会社 | 2−アセチルピリジン化合物の製造方法 |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
JP2023509453A (ja) * | 2020-01-03 | 2023-03-08 | ブルー オーク ファーマシューティカルズ インコーポレイテッド | Cns障害を処置するための化合物および組成物 |
GB202101734D0 (en) | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265890A (en) * | 1978-07-07 | 1981-05-05 | Smithkline Corporation | 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5639748A (en) * | 1991-08-05 | 1997-06-17 | Smithkline Beecham Corporation | 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity |
GB9116824D0 (en) | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
WO1993004866A1 (en) | 1991-09-11 | 1993-03-18 | Canon Kabushiki Kaisha | Improved cleaning member for ink jet head and ink jet device provided with said cleaning member |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
EP1213017A3 (en) | 2000-12-05 | 2003-11-12 | Akzo Nobel N.V. | Use of a 5-HT2C receptor agonist for the treatment of hot flushes |
JPWO2002074746A1 (ja) * | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
WO2003006466A1 (en) | 2001-07-13 | 2003-01-23 | Pharmacia & Upjohn Company | Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
BR0214529A (pt) | 2001-11-28 | 2006-05-30 | Upjohn Co | compostos terapêuticos |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
EP2332920A3 (en) | 2003-06-17 | 2011-12-21 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
EA016485B1 (ru) | 2003-06-17 | 2012-05-30 | Арена Фармасьютикалз, Инк. | Способы получения 3-бензазепинов |
TW200510324A (en) | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
WO2005042490A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
EA011011B1 (ru) * | 2004-02-25 | 2008-12-30 | Эли Лилли Энд Компани | 6-ЗАМЕЩЁННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-БЕНЗО[d]АЗЕПИНЫ В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ 5-HT |
CN102321023A (zh) | 2004-12-21 | 2012-01-18 | 艾尼纳制药公司 | (r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓盐酸盐的晶型 |
EA201100129A1 (ru) | 2004-12-23 | 2011-10-31 | Арена Фармасьютикалз, Инк. | Композиции и способы применения модулятора рецептора 5ht-2c |
JP5237810B2 (ja) * | 2005-09-01 | 2013-07-17 | イーライ リリー アンド カンパニー | 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン |
-
2006
- 2006-09-01 AU AU2006287202A patent/AU2006287202B2/en not_active Ceased
- 2006-09-01 PT PT68028596T patent/PT1924561E/pt unknown
- 2006-09-01 CA CA2619448A patent/CA2619448C/en not_active Expired - Fee Related
- 2006-09-01 WO PCT/US2006/034335 patent/WO2007028083A2/en active Application Filing
- 2006-09-01 US US11/996,751 patent/US20080269196A1/en not_active Abandoned
- 2006-09-01 PL PL06802859T patent/PL1924561T3/pl unknown
- 2006-09-01 SI SI200631496T patent/SI1924561T1/sl unknown
- 2006-09-01 CN CN2006800322352A patent/CN101258131B/zh not_active Expired - Fee Related
- 2006-09-01 JP JP2008529336A patent/JP5155864B2/ja not_active Expired - Fee Related
- 2006-09-01 ES ES06802859T patent/ES2397400T3/es active Active
- 2006-09-01 BR BRPI0615048-9A patent/BRPI0615048A2/pt not_active IP Right Cessation
- 2006-09-01 EP EP06802859A patent/EP1924561B1/en not_active Not-in-force
- 2006-09-01 DK DK06802859.6T patent/DK1924561T3/da active
-
2011
- 2011-06-09 US US13/156,575 patent/US8680091B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101258131B (zh) | 2013-07-24 |
SI1924561T1 (sl) | 2013-02-28 |
PL1924561T3 (pl) | 2013-03-29 |
EP1924561A2 (en) | 2008-05-28 |
ES2397400T3 (es) | 2013-03-06 |
AU2006287202A8 (en) | 2008-03-13 |
JP5155864B2 (ja) | 2013-03-06 |
WO2007028083A3 (en) | 2007-05-18 |
CA2619448A1 (en) | 2007-03-08 |
US8680091B2 (en) | 2014-03-25 |
CA2619448C (en) | 2013-08-13 |
AU2006287202B2 (en) | 2013-01-24 |
US20080269196A1 (en) | 2008-10-30 |
AU2006287202A1 (en) | 2007-03-08 |
BRPI0615048A2 (pt) | 2010-03-30 |
JP2009507034A (ja) | 2009-02-19 |
CN101258131A (zh) | 2008-09-03 |
PT1924561E (pt) | 2013-01-16 |
US20110269745A1 (en) | 2011-11-03 |
WO2007028083A2 (en) | 2007-03-08 |
EP1924561B1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1924561T3 (da) | 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister | |
DK1720836T3 (da) | 6-substituerede 2,3,4,5-tetrahydro-1h-benzo [d]azepiner som 5-ht2c-receptoragonister | |
GB0509275D0 (en) | Synthetic receptor | |
IL182090A0 (en) | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
ATE527355T1 (de) | Halbweiche immunstimulierende oligonukleotide der c-klasse | |
ATE469145T1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl- | |
ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
DK1797099T3 (da) | Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser | |
DK1824856T3 (da) | 2,4 (4,6)-pyrimidinderivater | |
ATE500244T1 (de) | 1,5-substituierte indol-2-yl amidderivative | |
BRPI0819014A2 (pt) | "descanso de braço" | |
SMAP200800029A (it) | 2-ammino-7,8-diidro-6h.pirido[4,3-d]pirimidin-5-oni | |
DE602007001681D1 (de) | 1,3-dioxan-carboxylsäuren | |
EP1830858A4 (en) | 3,6-BICYCLOLIDE | |
ATE517878T1 (de) | Substituierte 5-phenyl-3,6-dihydro-2-oxo-6h-ä1,3, 4üthiadiazine | |
GB0509276D0 (en) | Synthetic receptor | |
IL184677A0 (en) | Substituted 1,1,1-trifluoro-3-[(benzyl)- | |
IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
ATE538121T1 (de) | 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel | |
GB0425572D0 (en) | 1,7-Naphthyridines | |
DK1960510T3 (da) | Ammoniakspecifik 5'-xmp-aminasemutant | |
IL188111A0 (en) | 2,5-bis-diamimne [1,4] benzoquinone-derivatives | |
IL186226A0 (en) | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | |
GB2421964B (en) | Improved hanger | |
EP1711189A4 (en) | AZALIDE DERIVATIVES 8A 6,11-3C-BICYCLIC |